Results 171 to 180 of about 1,915,304 (214)
Drug-coated Balloons in the Treatment of Coronary Artery Disease: Results from the Drug Eluting Technologies Evaluation & Current Trends (DETECT) Survey. [PDF]
O'Callaghan D +9 more
europepmc +1 more source
True lumen stenting guided by intravascular ultrasound-confirmed wire repositioning from the subintimal space following balloon inflation during intravascular lithotripsy-induced coronary dissection: a case report. [PDF]
Tokuyama H.
europepmc +1 more source
Ultrathin-strut drug-eluting stents are associated with lower revascularization rates than drug-coated balloons in non-focal in-stent restenosis. [PDF]
Keskin B +13 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Vascular and Endovascular Surgery, 2017
Zhidong Ye, Xueqiang Fan, Mingsheng Sun
exaly +2 more sources
Zhidong Ye, Xueqiang Fan, Mingsheng Sun
exaly +2 more sources
Journal of Endovascular Therapy, 2020
Purpose: To evaluate the safety and efficacy of the novel SELUTION sustained-limus-release (SLR) drug-eluting balloon (DEB) in the treatment of femoropopliteal lesions.
T. Zeller +5 more
semanticscholar +1 more source
Purpose: To evaluate the safety and efficacy of the novel SELUTION sustained-limus-release (SLR) drug-eluting balloon (DEB) in the treatment of femoropopliteal lesions.
T. Zeller +5 more
semanticscholar +1 more source
The aim of this study was to compare neointimal modification with scoring balloon pre-dilation before drug-coated balloon (DCB) versus DCB standard therapy in patients presenting with drug-eluting stent (DES) restenosis.DCB angioplasty for the treatment ...
Robert A Byrne +2 more
exaly +2 more sources
Objective The aim of this study was to compare the drug-eluting balloon with self-expanding interwoven nitinol stent deployment in patients with complex femoropopliteal lesions.
Burak Teymen +3 more
semanticscholar +2 more sources
Annals of Vascular Surgery, 2020
PURPOSE To perform a meta-analysis comparing target lesion primary patency rates at 6 months and 1 year, and major procedure-associated complications between drug-eluting balloon (DEB) and plain balloon angioplasty (PBA) for the treatment of ...
Ye Yuan, W. Cheng, Huijun Lu
semanticscholar +1 more source
PURPOSE To perform a meta-analysis comparing target lesion primary patency rates at 6 months and 1 year, and major procedure-associated complications between drug-eluting balloon (DEB) and plain balloon angioplasty (PBA) for the treatment of ...
Ye Yuan, W. Cheng, Huijun Lu
semanticscholar +1 more source
Future Cardiology, 2020
Endovascular treatment has become first line therapy for the treatment of femoropopliteal disease. Drug-coated devices play a key role in maintaining vessel patency.
Tanja Böhme +4 more
semanticscholar +1 more source
Endovascular treatment has become first line therapy for the treatment of femoropopliteal disease. Drug-coated devices play a key role in maintaining vessel patency.
Tanja Böhme +4 more
semanticscholar +1 more source
A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. [PDF]
ObjectivesThis study sought to define the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty alone.BackgroundDrug-coated balloon angioplasty is associated with ...
Hans-Josef Feistritzer +1 more
exaly +2 more sources

